Highly selective drug targeting is an important goal in the development of cancer nanotechnologies. In an effort to improve tumor targeting a method was developed to formulate cell membrane lipid-extracted nanoliposomes (CLENs). The main ingredients were extracted directly from the membrane of cancer cells. For this study we used three different breast cancer cell lines (4 T1, BT-20, and SK-BR-3). As controls for the normal breast and cancer tissue environments we employed the normal breast fibroblast (CRL-2089) and ovarian cancer (SK-OV-3) cell lines, respectively. We evaluated physicochemical properties, efficiency of drug loading, cellular uptake, and cytotoxicity. The mean diameter and zeta potential values for the 5 different CLENs were 202 ± 38 nm and − 15 ± 3.8 mv, respectively. Doxorubicin hydrochloride (5 mol%) increased the size of 4 T1-CLENs from 158 ± 2 nm to 212 ± 59 nm, with no significant change in the negatively-charged surface potential. Percent of drug loaded ranged from 40 to 93%, varying according to the ratio of lipid extract to conventional components employed. The additional inclusion of cholesterol and DPPE-PEG5000 increased drug loading in CLENs, similar to Doxil preparations. The most promising cellular uptake and cytotoxicity profiles were observed when the lipid ingredients were derived from the eventual target cell. Given the ability of CLENs to better recognize target cells compared to nanosystems consisting of non-specific lipid extracts or conventional liposome ingredients alone, CLENs has demonstrated early promise as a nano-delivery system for cancer treatment.

中文翻译：

---

由靶细胞衍生的细胞膜特异性细胞脂质提取物组成的纳米制剂：理化性质和体外乳腺癌细胞模型评估

高度选择性的药物靶向是癌症纳米技术发展的重要目标。为了改善肿瘤靶向性，开发了一种方法来配制细胞膜脂质提取的纳米脂质体（CLENs）。主要成分直接从癌细胞膜中提取。在这项研究中，我们使用了三种不同的乳腺癌细胞系（4种T1，BT-20和SK-BR-3）。作为正常乳腺和癌组织环境的对照，我们分别使用了正常乳腺成纤维细胞（CRL-2089）和卵巢癌（SK-OV-3）细胞系。我们评估了理化特性，药物装载效率，细胞摄取和细胞毒性。5种不同的CLEN的平均直径和Zeta电位值分别为202±38 nm和− 15±3.8 mv。盐酸阿霉素（5 mol％）将4个T1-CLEN的尺寸从158±2 nm增加到212±59 nm，带负电的表面电势没有明显变化。载药的百分比范围为40％至93％，具体取决于脂质提取物与所用常规成分的比例。类似于Doxil制剂，胆固醇和DPPE-PEG5000的额外加入增加了CLENs的载药量。当脂质成分来自最终靶细胞时，观察到最有希望的细胞摄取和细胞毒性概况。与仅由非特异性脂质提取物或常规脂质体成分组成的纳米系统相比，鉴于CLENs能够更好地识别靶细胞的能力，CLENs已被证明是早期有望作为癌症治疗的纳米递送系统。